Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	226.61	82.25	124.78	258.89	304.96	167.06
Short-Term Investments	0	0	42.09	50.44	0	34.65
Cash & Cash Equivalents	226.61	82.25	166.86	309.33	304.96	201.71
Cash Growth	39.59%	-50.71%	-46.06%	1.43%	51.19%	48.29%
Receivables	54.61	48.49	33.73	22.93	12.39	0
Inventory	73.1	65.62	35.2	34.39	16.14	0
Other Current Assets	11.29	4.7	10.89	-37.69	12.41	10.01
Total Current Assets	365.61	201.07	246.68	328.97	345.9	211.71
Property, Plant & Equipment	7.4	4.68	1.2	2.56	7.31	2.68
Goodwill and Intangibles	0.06	0.06	0.06	0.06	0.06	0.06
Other Long-Term Assets	0	0	0	50	0	0
Total Long-Term Assets	7.45	4.73	1.26	52.62	7.36	2.73
Total Assets	373.06	205.8	247.94	381.59	353.26	214.45
Accounts Payable	28.43	31.72	23.04	17.56	51.98	28.86
Deferred Revenue	29.35	25.4	3.51	6.32	1.66	2.15
Current Debt	46.03	36.38	25.14	12.69	7.98	5.69
Other Current Liabilities	60.7	62.72	40.62	36.79	32.45	29.38
Total Current Liabilities	164.51	156.22	92.31	73.35	94.07	66.08
Long-Term Debt	502.85	504.57	479.41	504.55	354.03	128.42
Other Long-Term Liabilities	0	0	0	0.63	1.29	0
Total Long-Term Liabilities	502.85	504.57	479.41	505.18	355.32	128.42
Total Liabilities	667.36	660.79	571.72	578.53	449.39	194.5
Total Debt	548.87	540.95	504.55	517.24	362.01	134.11
Debt Growth	6.95%	7.21%	-2.45%	42.88%	169.94%	-
Retained Earnings	-1,488.26	-1,549.28	-1,340.04	-1,106.38	-838.82	-695.27
Comprehensive Income	0	0	-0	-0.03	0	0.02
Shareholders' Equity	-294.3	-454.99	-323.78	-196.94	-96.13	19.95
Net Cash / Debt	-322.26	-458.7	-337.69	-207.9	-57.05	67.6
Net Cash / Debt Growth	-	-	-	-	-	-50.30%
Net Cash Per Share	-1.70	-4.45	-5.09	-7.19	-2.08	2.50
Working Capital	201.09	44.84	154.38	255.62	251.83	145.63
Book Value Per Share	-1.74	-4.41	-4.88	-6.81	-3.50	0.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).